Davis and Dietrich’s response to Abramson and colleagues’ article on statins in low risk people

Abramson and colleagues question the benefit of statins in low risk patients, as recommended by the new cholesterol treatment guidelines.1 2 This conclusion is based on the authors’ evaluation of a meta-analysis performed by the Cholesterol Treatment Trialists’ (CTT) Collaborators.3 Firstly, they state that, in the setting of primary prevention, statins have not been shown to affect all cause mortality.1 In the JUPITER trial, 17 802 otherwise healthy participants were randomised to treatment with rosuvastatin 20 mg daily or placebo.4 Over 97% of study participants had less than a 10% five …